The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics

D. Singh, L. Cass, F. Pétavy, B. O‘Connor (Manchester, Stevenage, Greenford, London, United Kingdom)

Source: Annual Congress 2008 - Novel treatments for respiratory disease
Session: Novel treatments for respiratory disease
Session type: Oral Presentation
Number: 2732
Disease area: Airway diseases

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Singh, L. Cass, F. Pétavy, B. O‘Connor (Manchester, Stevenage, Greenford, London, United Kingdom). The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics. Eur Respir J 2008; 32: Suppl. 52, 2732

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine
Source: Annual Congress 2007 - New drugs for asthma
Year: 2007


Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma
Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease
Year: 2010

The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen
Source: Annual Congress 2011 - Asthma management and response
Year: 2011

The different effect of NO-synthase inhibitors in allergen and toluene-induced airway hyperreactivity
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010

Inhaled IL-4/IL-13 antagonist decreases response to antigen challenge in atopic asthmatic subjects
Source: Eur Respir J 2007; 30: Suppl. 51, 490s
Year: 2007

Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459
Source: Eur Respir J 2013; 41: 46-52
Year: 2013



Protective effect of inhaled iloprost on specific bronchial challenge in aspirin-sensitive asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 471s
Year: 2002

Combined treatment with fluticasone plus salmeterol protects against allergen induced asthmatic responses and subsequent increase in sputum eosinophils
Source: Eur Respir J 2002; 20: Suppl. 38, 189s
Year: 2002

Inhibition by roflumilast of airway hyperresponsiveness to adenosine and pulmonary inflammation in allergen challenged Brown-Norway rats
Source: Eur Respir J 2001; 18: Suppl. 33, 35s
Year: 2001

Influence of formoterol alone and its fixed combination with budesonide on airway responsiveness and airway inflammation induced by repeated low dose allergen challenge
Source: Eur Respir J 2007; 30: Suppl. 51, 749s
Year: 2007

Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice
Source: Eur Respir J 2009; 34: 200-208
Year: 2009



The effect of single dose montelukast and desloratadine, alone and in combination, on the allergen induced late airway response in atopic asthma
Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment
Year: 2008



Repeated inhaled airway allergen challenge model in asthma
Source: Annual Congress 2009 - Inflammation and airways
Year: 2009

Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro
Source: Eur Respir J 2002; 20: Suppl. 38, 91s
Year: 2002

The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 414s
Year: 2003

Montelukast as add-on therapy to β-agonists and late airway response
Source: Eur Respir J 2007; 30: 56-61
Year: 2007



Effect of formoterol with or without budesonide in repeated low-dose allergen challenge
Source: Eur Respir J 2009; 33: 747-753
Year: 2009



Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma
Source: Eur Respir J 2002; 20: 1080-1087
Year: 2002



HIF-1α inhibitor, 2ME2, attenuates airway inflammation and hyperresponsiveness in allergic airway disease
Source: Annual Congress 2008 - Novel therapeutic approaches and immunological mechanisms in airway cell pathobiology
Year: 2008


Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma
Source: Eur Respir J 2003; 21: 1046-1049
Year: 2003